Why the study?
Does macitentan reduce morbidity and mortality in patients with pulmonary arterial hypertension?
Does macitentan reduce morbidity and mortality in patients with pulmonary arterial hypertension?
Macitentan significantly reduces morbidity and mortality in patients with pulmonary arterial hypertension.
Supports macitentan initiation in pulmonary arterial hypertension; confirms morbidity-mortality benefit of endothelin antagonism in randomized settings.
Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.).
No takes yet. Share an insight, caveat, or question.
Pulido et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: